Biomea Fusion, Inc.

NASDAQ:BMEA

Biotechnology

Healthcare
$0.74 -2.50%

-$0.03 today

Market cap
$53.18M
Beta
-0.33
P/E (TTM)
-1.9
EPS (TTM)
-$0.62
52W Low $0.87High $2.99

Volume 3.50M

Average 1.52M

BMEA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Biomea Fusion, Inc.NASDAQ: BMEA

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 72.3M shares rose 97.4% year over year, ahead of the +55.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +21.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +97.4% holds above the trailing-twelve-month pace of +55.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
72.3M+0.0% QoQ
Last fiscal yearDec 2025
52.23M+44.7% YoY
LTMMar 2026
56.46M+55.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+97.4%——
1 year+44.7%——
3-year CAGR+21.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
52.23M USD
Year-over-year change
+44.7%
4-year CAGR
+21.6%

Weighted Avg Shares vs competitors

How BMEA compares with its peers on the latest reported figures

  • BMEA's LTM Mar 2026 weighted avg shares of 56.46M shares is the 4th highest of the 9 companies compared; the peer median is 53.4M shares.
  • Its year-over-year change of +55.6% is the 5th highest of 9, against a peer median of +67.9%.
  • Over three fiscal years its annual growth of +21.3% compares with a peer median of +16.8%.
BMEA Competitors Peer median
Weighted Avg Shares for BMEA and competitors
Company Period LTM YoY 3-year CAGR
CBUSCibus, Inc.LTM Mar 2026301.04M +1164.8%-7.5%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026107.08M +1278.7%+372.5%
GUTSFractyl Health, Inc. Common StockLTM Mar 202666.33M +37.1%+16.8%
BMEABiomea Fusion, Inc.LTM Mar 202656.46M +55.6%+21.3%
ALXOALX Oncology Holdings Inc.LTM Mar 202653.9M +2.3%+9.7%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 202652.9M +2.4%+4.8%
CAMPCAMP4 Therapeutics CorporationLTM Mar 202637.54M +102.0%—
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
STROSutro Biopharma, Inc.LTM Mar 20266.42M -22.0%+18.8%
Peer median (excluding BMEA) 53.4M+67.9%+16.8%

Competitors are the stored peer set for BMEA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00001.41M
Gross Profit0000(1.41M)
Gross Margin—————
Research & Development28M62.71M102.55M118.09M61.98M
Selling, General & Admin13.67M20.92M23.59M25.99M19.33M
Operating Expenses41.67M83.63M126.14M144.07M79.9M
Depreciation & Amortization249K691K1.52M1.75M1.41M
EBITDA(41.32M)(81.14M)(115.74M)(136.68M)(60.39M)
EBITDA Margin—————
Operating Income(41.67M)(83.63M)(126.14M)(144.07M)(81.31M)
Operating Margin—————
Interest Income100K1.81M8.88M5.64M1.86M
Interest Expense00000
Other Income / Expenses100K1.81M8.88M5.64M19.51M
Income Before Tax(41.57M)(81.83M)(117.26M)(138.43M)(61.8M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(41.57M)(81.83M)(117.26M)(138.43M)(61.8M)
Net Margin—————
EPS (Basic)(1.74)(2.80)(3.44)(3.83)(1.18)
EPS (Diluted)(1.74)(2.80)(3.44)(3.83)(1.18)
Weighted Avg Shares23.86M29.27M34.11M36.11M52.23M
Weighted Avg Shares (Diluted)23.86M29.27M34.11M36.11M52.23M

Biomea Fusion, Inc.

NASDAQ:BMEA

Intrinsic Alpha fair value

Locked

Current Price

$0.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.